Poor
Not Aligned
Patient Risk:
Medium
Summary
The AI claims include many unsupported disease-prevention and mechanistic statements (e.g., cancer prevention, neuroprotection/cognitive decline, hearing loss specificity) that are not present in the provided FDA label excerpts. Only a limited portion aligns with the label’s indicated antithrombotic effect and bleeding risk framework.
Category Scores
Accurate Statements
Aspirin (acetylsalicylic acid, ASA) is a nonsteroidal anti-inflammatory drug (NSAID).
Not supported or contradicted by the provided label excerpts.
In low doses, aspirin can help prevent blood clots.
Partially supported in general terms by label mechanism: “additive antiplatelet effects of dipyridamole and aspirin” (Section 12.1). The specific “low doses” and “blood clots” phrasing is not explicitly supported.
Aspirin can cause stomach ulcers.
Partially supported by label warning that physicians should remain alert for signs of ulceration and bleeding (Section 5.1 under GI side effects / Peptic Ulcer Disease).
Aspirin can cause gastrointestinal bleeding.
Supported: “GI side effects include… gross GI bleeding” and ESPS2 GI bleeding event rates (Section 5.1).
Long-term aspirin use can increase the risk of bleeding.
Supported in concept by label “increases the risk of bleeding” (Section 5.1). The explicit “long-term” is not specified in the excerpt.
Unsupported Statements
Aspirin works by inhibiting the production of prostaglandins.
Mechanism of action in the provided excerpt is antiplatelet effects (Section 12.1). No prostaglandin-inhibition statement is included.
In low doses, aspirin can reduce the risk of heart attack.
No heart attack risk-reduction claim appears in provided label excerpts (Section 1/14).
In low doses, aspirin can reduce the risk of stroke.
The label indication is for Aspirin and Extended-Release Dipyridamole capsule reducing risk of stroke in patients with prior TIA or completed ischemic stroke due to thrombosis (Section 1). The provided claim attributes effect to “aspirin” alone and omits the specific product/patient population.
In higher doses, aspirin can provide relief from pain and inflammation.
Not present in provided label excerpts for this product (Sections 1 and dosing/excerpts supplied).
Aspirin may help prevent certain types of cancer, such as colon cancer.
No cancer prevention claims appear in provided label excerpts.
Aspirin may help prevent certain types of cancer, such as breast cancer.
No cancer prevention claims appear in provided label excerpts.
Aspirin may have neuroprotective effects.
No neuroprotective claim appears in provided label excerpts.
Aspirin may potentially reduce the risk of age-related cognitive decline.
No cognitive decline claim appears in provided label excerpts.
Aspirin may potentially reduce the risk of dementia.
No dementia claim appears in provided label excerpts.
Aspirin can increase the risk of gastrointestinal bleeding, particularly when taken in high doses or for extended periods.
Label excerpt states aspirin-containing product increases bleeding risk and lists risk factors (e.g., other drugs/ chronic NSAID use), but does not specify “high doses” or “extended periods” for GI bleeding in the provided text.
Long-term aspirin use may increase the risk of kidney damage.
Provided renal warning is to avoid in severe renal failure (GFR <10 mL/min) (Sections 5.2, 8.6). No statement about “long-term” causing kidney damage is included.
Long-term aspirin use may increase the risk of kidney disease.
Same issue as above; provided excerpts do not state long-term causation.
Aspirin has been linked to hearing loss.
No hearing loss information appears in provided label excerpts.
Aspirin-related hearing loss is particularly associated with high doses or extended periods of use.
No hearing loss information appears in provided label excerpts.
The increased risk of bleeding from aspirin is particularly in older adults.
No “older adults” bleeding-specific statement appears in provided label excerpts.
Some studies suggest that long-term aspirin use may be associated with cognitive decline.
No cognitive decline/dementia association appears in provided label excerpts.
Some studies suggest that long-term aspirin use may be associated with dementia.
No dementia association appears in provided label excerpts.
Certain genetic variants can affect an individual's response to aspirin.
No genetic/ pharmacogenomic statements appear in provided label excerpts.
Certain genetic variants can increase an individual's risk of bleeding from aspirin.
No genetic/ pharmacogenomic statements appear in provided label excerpts.
Certain genetic variants can increase an individual's risk of other adverse effects from aspirin.
No genetic/ pharmacogenomic statements appear in provided label excerpts.
Contradictions
Important Omissions
Indication-specific context: The label indication is for Aspirin and Extended-Release Dipyridamole capsule to reduce risk of stroke in patients with transient ischemia of the brain or completed ischemic stroke due to thrombosis. The AI’s stroke-related claims did not reflect this specific product and patient population.
Importance:
Moderate
Product administration/dosing details: Twice-daily dosing schedule and instructions (swallow whole; not interchangeable with individual components) are not addressed by the AI claims.
Importance:
Moderate
Contraindications relevant to aspirin component: hypersensitivity, NSAID allergy/asthma-rhinitis-nasal polyps syndrome, and pediatric viral infections/ Rey e syndrome are not addressed.
Importance:
Moderate
Renal/hepatic precautions: Avoid in severe renal failure (GFR <10 mL/min) and caution regarding hepatic enzymes/ hepatic failure reported with dipyridamole; AI only speculated about kidney damage.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
While the AI correctly notes increased bleeding/GI risk and ulceration alerting in general terms, it introduces many unsupported claims (cancer prevention, neurocognitive benefits, hearing loss, genetic risk modifiers). Unsupported benefit claims could mislead users, and unsupported risk details may distract from label-specific contraindications/precautions (e.g., avoidance in severe renal failure; contraindications for NSAID allergy and pediatric viral infection).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Majority of claims are not supported by the provided FDA label excerpts for Aspirin and Extended-Release Dipyridamole Capsules (e.g., cancer prevention, neuroprotection/cognitive decline/dementia, hearing loss linkage, genetic variants). Stroke-risk claims are not aligned to the specific labeled product and patient population.
Suggested Improvement
Restrict claims to what is present in the supplied label excerpts: labeled indication (stroke reduction in specified TIA/prior ischemic stroke patients), the antiplatelet additive mechanism (Section 12.1), and label-supported warnings/precautions such as bleeding and GI side effects plus contraindications and avoidance criteria (e.g., severe renal failure GFR <10 mL/min; NSAID allergy; pediatric viral infection/Reye syndrome). Remove speculative or uncited findings not appearing in the label excerpts.